Sirius Therapeutics
Last verified 2026-06-17. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $100.0Mattributed |
|---|---|
| Latest round | series-b, $50.0M, 2025-05-01attributed |
| Founded | 2021 |
| Headquarters | San Diego, United States |
| Industry | bio |
| Stage | series-b+ |
| Website | siriustx.com |
Sirius Therapeutics is a clinical-stage biotech developing long-acting siRNA therapies for cardiovascular disease, led by SRSD107, a Factor XI inhibitor for thromboembolic disorders. It targets patients at risk of thrombosis where anticoagulants raise bleeding risk. Its edge is selective Factor XI silencing with minimal impact on normal hemostasis.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-05-01 | series-b | $50.0M | undisclosed |
Detected tech stack
hsts, nginx, openresty
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series B, $50.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $100.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | siriustx.com, read 2026-06-17 |
| Description | self-reported | siriustx.com, read 2026-06-17 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.